VYNDAQEL FDA approval date

The FDA approved VYNDAQEL on 3 May 2019.

FDA approval date
3 May 2019

Drug identity has not yet been verified against registry records

Also recorded as TAFAMIDIS MEGLUMINE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2019-05-03DayVYNDAQELFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA211996", "applicant_as_listed_by_fda": "FOLDRX PHARMS", "brand_names": ["VYNDAQEL"], "active_ingredients": ["TAFAMIDIS MEGLUMINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190503", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026